Materiobiomodulated ROS Therapy for De Novo Hair Growth
Advanced Materials · 2024-05 · 36 (21)
DOI: 10.1002/adma.202311459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 21.02.2024. Verfasst von Long Bai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Ultrafine Materials of Ministry of Education, Engineering Research Center for Biomedical Materials of Ministry of Education, Front…. Hauptthemen laut MEDLINE: Hair Follicle, Indoles, Nanoparticles, Polymers. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 111 project, Excellent Academic Leader Project of Shanghai Science and Technology Committee.
Abstract (Originalsprache)
Hair loss is characterized by the inability of hair follicles (HFs) to enter the telogen‐anagen transition (TAT) and lack of de novo HFs. Current pharmaceutical therapies and surgical modalities have been largely limited to regulating hair regrowth efficiently without side effects and lacking treatment compliance. Here, this work proposes a materiobiomodulation therapy (MBMT), wherein polydopamine (PDA) nanoparticles with redox activity can be modulated to have a stoichiometric ROS (H 2 O 2 ) donating ability. These nanoparticles can intracellularly deliver ROS with high‐efficiency via the clathrin‐dependent endocytosis process. Utilizing homozygote transgenic HyPerion (a genetically‐encoded H 2 O 2 biosensor) mice, this work also achieves in vivo dynamic monitoring of intracellular H 2 O 2 elevation induced by ROS donators. Subcutaneous administration with ROS donators results in rapid onset of TAT and subsequent hair regrowth with a specific ROS “hormesis effect.” Mechanistically, ROS activate β‐catenin‐dependent Wnt signaling, upregulating hair follicle stem cell expression. This work further develops a microneedles patch for transdermal ROS delivery, demonstrating long‐term, low‐dose ROS release. Unlike photobiomodulation therapy (PBMT), MBMT requires no external stimuli, providing a convenient and efficient approach for clinical hair loss treatment. This material‐HF communication implicates new avenues in HF‐related diseases, achieving targeted ROS delivery with minimal side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Ultrafine Materials of Ministry of Education, Engineering Research Center for Biomedical Materials of Ministry of Education, Frontiers Science Center for Materiobiology and Dynamic Chemistry, School o…
- Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
- State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
- Optogenetics & Synthetic Biology Interdisciplinary Research Center, Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai University, Shanghai, 200444, China.
Förderung
- National Natural Science Foundation of China
- 111 project
- Excellent Academic Leader Project of Shanghai Science and Technology Committee
- Young Elite Scientist Sponsorship Program by China Association for Science and Technology
- Higher Education Discipline Innovation Project
Zitieren
APA
Bai, L., Wang, Y., Wang, K., Chen, X., Zhao, Y., Liu, C., & Qu, X. (2024). Materiobiomodulated ROS Therapy for De Novo Hair Growth. Advanced Materials, 36(21). https://doi.org/10.1002/adma.202311459
Vancouver
Bai L, Wang Y, Wang K, Chen X, Zhao Y, Liu C, et al. Materiobiomodulated ROS Therapy for De Novo Hair Growth. Advanced Materials. 2024;36(21). doi:10.1002/adma.202311459
BibTeX
@article{Bai2024,
author = {Bai, Long and Wang, Yifei and Wang, Kun and Chen, Xiaoqian and Zhao, Yuzheng and Liu, Changsheng and Qu, Xue},
title = {Materiobiomodulated ROS Therapy for De Novo Hair Growth},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {21},
doi = {10.1002/adma.202311459}
}
EUVIMED